Roche Holding Zukünftiges Wachstum

Future Kriterienprüfungen 3/6

Roche Holding wird ein jährliches Gewinn- und Umsatzwachstum von 8.5% bzw. 3.7% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 8.5% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 36.3% betragen.

Wichtige Informationen

8.6%

Wachstumsrate der Gewinne

8.6%

EPS-Wachstumsrate

Pharmaceuticals Gewinnwachstum	11.4%
Wachstumsrate der Einnahmen	3.7%
Zukünftige Eigenkapitalrendite	36.4%
Analystenabdeckung	Good
Zuletzt aktualisiert	25 Jun 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

We Think Roche Holding (VTX:ROG) Can Stay On Top Of Its Debt

Apr 17

Roche Holding's (VTX:ROG) Shareholders Will Receive A Bigger Dividend Than Last Year

Mar 06

Roche Holding's (VTX:ROG) Shareholders Will Receive A Bigger Dividend Than Last Year

Feb 09

Gewinn- und Umsatzwachstumsprognosen

SWX:ROG - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (CHF Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	66,718	15,789	15,387	20,284	15
12/31/2025	63,999	14,757	14,699	19,240	17
12/31/2024	60,610	13,251	13,500	17,843	17
12/31/2023	60,441	11,498	11,446	16,095	N/A
9/30/2023	61,486	11,263	11,759	16,313	N/A
6/30/2023	63,142	11,028	12,683	17,142	N/A
3/31/2023	64,784	11,725	13,273	17,779	N/A
12/31/2022	65,814	12,421	13,251	17,803	N/A
9/30/2022	66,716	13,539	15,384	19,869	N/A
6/30/2022	67,617	14,657	17,516	21,935	N/A
3/31/2022	66,734	14,294	16,972	21,456	N/A
12/31/2021	65,850	13,930	16,427	20,976	N/A
9/30/2021	63,974	13,975	15,197	20,346	N/A
6/30/2021	62,098	14,019	13,967	19,716	N/A
3/31/2021	61,221	14,157	12,922	19,141	N/A
12/31/2020	60,343	14,295	11,876	18,566	N/A
9/30/2020	61,361	13,626	13,799	19,949	N/A
6/30/2020	62,378	12,957	15,722	21,332	N/A
3/31/2020	63,065	13,227	16,607	21,859	N/A
12/31/2019	63,751	13,497	17,491	22,385	N/A
9/30/2019	62,736	12,654	16,077	21,210	N/A
6/30/2019	61,721	11,810	14,662	20,034	N/A
3/31/2019	60,609	11,155	14,860	20,007	N/A
12/31/2018	59,497	10,500	15,057	19,979	N/A
9/30/2018	58,611	10,483	14,526	19,131	N/A
6/30/2018	57,725	10,465	13,995	18,283	N/A
3/31/2018	56,736	9,549	13,903	18,154	N/A
12/31/2017	55,746	8,633	13,811	18,024	N/A
9/30/2017	54,961	9,154	N/A	17,578	N/A
6/30/2017	54,176	9,675	N/A	17,132	N/A
3/31/2017	53,406	9,626	N/A	16,067	N/A
12/31/2016	52,636	9,576	N/A	15,001	N/A
9/30/2016	52,109	9,332	N/A	14,678	N/A
6/30/2016	51,581	9,087	N/A	14,354	N/A
3/31/2016	50,992	8,975	N/A	14,803	N/A
12/31/2015	50,403	8,863	N/A	15,251	N/A
9/30/2015	50,364	8,908	N/A	15,077	N/A
6/30/2015	50,324	8,953	N/A	14,902	N/A
3/31/2015	50,095	9,143	N/A	15,416	N/A
12/31/2014	49,866	9,332	N/A	15,930	N/A
9/30/2014	49,300	10,044	N/A	16,160	N/A
6/30/2014	48,733	10,756	N/A	16,389	N/A
3/31/2014	48,673	10,960	N/A	16,081	N/A
12/31/2013	48,612	11,164	N/A	15,772	N/A
9/30/2013	48,502	11,167	N/A	15,467	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: ROGDas prognostizierte Gewinnwachstum (8.5% pro Jahr) liegt über der Sparquote (0.2%).

Ertrag vs. Markt: ROGDie Erträge des Unternehmens (8.5% pro Jahr) werden voraussichtlich schneller wachsen als der Markt Swiss (8.2% pro Jahr).

Hohe Wachstumserträge: ROGDie Erträge des Unternehmens werden voraussichtlich steigen, jedoch nicht deutlich.

Einnahmen vs. Markt: ROGDie Einnahmen des Unternehmens (3.7% pro Jahr) werden voraussichtlich langsamer wachsen als der Markt Swiss (4.4% pro Jahr).

Hohe Wachstumseinnahmen: ROGDie Einnahmen des Unternehmens (3.7% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: ROGDie Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich hoch sein (36.3%)

Roche Holding Zukünftiges Wachstum

Future Kriterienprüfungen 3/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Roche Holding AG Provides Earnings Guidance for the Year 2024

Roche Holding AG Confirms Outlook for 2023

Roche Holding AG Confirms Earnings Guidance for the Year 2023

Recent updates

Roche Holding AG to Report Q2, 2024 Results on Jul 25, 2024

Roche Announces the European Commission Grants Marketing Authorisation for OCREVUS (Ocrelizumab) Subcutaneous for the Treatment of Relapsing Multiple Sclerosis and Primary Progressive Multiple Sclerosis

Roche Launches New Highly-Sensitive Test to More Easily Diagnostic Patients Who May Have B-Cell Lymphoma

Roche’s Phase III STARGLO study demonstrates Columvi significantly extends survival in people with relapsed or refractory diffuse large B-cell lymphoma

Roche Holding AG Announces U.S. Food and Drug Administration Accepted the New Drug Application and Granted Priority Review to Inavolisib, an Investigational, Oral Therapy, in Combination with Palbociclib (Ibrance®) and Fulvestrant

Roche Announces Management and Board Committee Changes

Roche Receives FDA Device Designation for Blood Test Measuring Lp(a)

Roche Reports Positive Phase I Results for Its Dual GLP-1/GIP Receptor Agonist CT-388 in People with Obesity

Roche Announces FDA Approval of One of the First HPV Self- Collection Solutions in the U.S., Expanding Access and Screening Options to Help Eliminate Cervical Cancer

Roche Holding AG Provides Earnings Guidance for the Year 2024

FDA Approves Roche’s Alecensa as the First Adjuvant Treatment for People with ALK-Positive Early-Stage Lung Cancer

Roche Holding AG Announces Data from the Phase III OCARINA II Study (S31.006) of OCREVUS®? (ocrelizumab)

We Think Roche Holding (VTX:ROG) Can Stay On Top Of Its Debt

Roche Receives FDA Breakthrough Device Designation for Blood Test to Support Early Alzheimer's Disease Diagnosis

Roche Receives FDA Approval for the First Molecular Test to Screen for Malaria in Blood Donors

Roche Holding AG, Annual General Meeting, Mar 12, 2024

Upcoming dividend of CHF9.60 per share

Roche Holding's (VTX:ROG) Shareholders Will Receive A Bigger Dividend Than Last Year

Roche and Alnylam Report Positive Topline Results from the Phase II KARDIA-2 Study in People with Hypertension

Roche Announces FDA Approves Xolair as First and Only Medicine for Children and Adults with One or More Food Allergies

Roche Launches Three New Factor Xa Inhibitor Coagulation Tests to Meet Growing Patient Need

Roche Holding's (VTX:ROG) Shareholders Will Receive A Bigger Dividend Than Last Year

Roche Holding's (VTX:ROG) Soft Earnings Are Actually Better Than They Appear

Full year 2023 earnings: EPS and revenues miss analyst expectations

Dividend increased to CHF9.60

Roche Announces New 72-Week Data from Two Global Phase III Studies, BALATON and COMINO, Evaluating Vabysmo® (Faricimab) in Macular Edema Due to Branch and Central Retinal Vein Occlusion (BRVO and CRVO)

Roche Holding AG Proposes Dividend

Roche Holding AG (SWX:ROG) completed the acquisition of Carmot Therapeutics Inc. from a group of shareholders.

Roche Holding AG (SWX:ROG) completed the acquisition of Carmot Therapeutics Inc. from a group of shareholders.

European Commission Approves Roche's Tecentriq SC, the EU's First PD-(L)1 Cancer Immunotherapy Subcutaneous Injection for Multiple Cancer Types

Market Cool On Roche Holding AG's (VTX:ROG) Earnings

Roche Holding AG to Report Fiscal Year 2023 Results on Feb 01, 2024

Roche Announces New Data from Its CD20xCD3 T-Cell Engaging Bispecific Antibody Programme Were Presented At the 65Th American Society of Hematology Annual Meeting & Exposition

Roche Announces New Data Reinforce the Benefit of Early Preventative Treatment with Hemlibra for Babies with Severe Haemophilia A

Roche Presents Positive Results from the Phase III INAVO120 Study Evaluating Inavolisib in Combination with Palbociclib and Fulvestrant as a First-Line Treatment for People with PIK3CA-Mutation

We Think Roche Holding (VTX:ROG) Can Stay On Top Of Its Debt

Roche Holding AG (SWX:ROG) entered into a definitive merger agreement to acquire Carmot Therapeutics Inc. from a group of shareholders for approximately $2.7 billion.

Roche Expands Hepatitis Diagnostics Portfolio to Help Clinicians Diagnose and Monitor Patients with Acute or Chronic Hepatitis B Infection

Roche Expands Hepatitis Diagnostics Portfolio to Help Clinicians Diagnose and Monitor Patients with Acute or Chronic Hepatitis B Infection

Roche Launches Automated Serology Hepatitis E Virus Tests, Including A Test to Detect Acute Hev Infections, Recommended in the New Who 2023 Essential Diagnostics List

Roche's Subcutaneous Injection of Tecentriq Recommends by the EU's CHMP for Multiple Cancer Types

Roche Announces its Elecsys NfL Test Receives FDA Breakthrough Device Designation from the U.S. Food and Drug Administration

Roche Announces EMBARK Trial in Duchenne Muscular Dystrophy

United States Food and Drug Administration Approves Roche's Vabysmo for the Treatment of Retinal Veinocclusion (RVO)

Roche Holding AG Confirms Outlook for 2023

Roche Announces Roche IL-6 Is the First Immunoassay Approved to Aid Sepsis Diagnosis in Newborns

Roche Announces New Clinical and Real-World Data for Orevus (Ocrelizumab)

Roche Holding AG Announces Late-Breaking Data from the Phase III Ocarina III Study as an Investigational Twice-Yearly, 10-Minute Subcutaneous Injection on Pharmacokinetic, Biomarker, and Mri Measures in Patients with Relapsing or Primary Progressive Multiple Sclerosis

Roche Presents Positive Results from the Primary Analysis of the Ongoing Rainbowfish Study Assessing the Efficacy and Safety of Evrysdi

Roche and Alnylam Report Positive Topline Results from Phase 2 Study Kardia-1 of Zilebesiran

Roche’S Alecensa Delivers Unprecedented Phase III Results for People with ALK-positive early-stage lung cancer

Roche Holding AG Tecentriq Becomes the First Subcutaneous Anti-PD-(L)1 Cancer Immunotherapy Available to Patients in Great Britain, Reducing Treatment Time to Just Minutes

Is Roche Holding (VTX:ROG) A Risky Investment?

Roche Provides Update on Phase III Skyscraper-01 Study in PD-L1-High Metastatic Non-Small Cell Lung Cancer

New minor risk - Earnings quality

Roche Holding AG Confirms Earnings Guidance for the Year 2023

Roche Announces New Clinical and Real-World Data for Vabysmo at ASRS Reveal Improved Outcomes for People with Two Leading Causes of Vision Loss

Roivant Sciences Reportedly Near Deal to Sell Stomach Drug to Roche for over $7 Billion

Roche Announces Positive Phase III Results for Roche’s OCREVUS (ocrelizumab) Twice a Year, 10-minute Subcutaneous Injection in Patients with Multiple Sclerosis

European Commission Approves Roche Holding AG's Fixed-Term Columvi (Glofitamab) for People with Relapsed or Refractory Diffuse Large B-Cell L-Cell Lymphoma

Roche Receives FDA Clearance for Additional Alzheimer's Disease Cerebrospinal Fluid Assays, Supporting Timely Diagnosis and Treatment Decision-Making

Roche Looking to Sell or Shut Down Vacaville, California Plant

Gewinn- und Umsatzwachstumsprognosen

Analystenprognosen zum zukünftigen Wachstum

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Wachstumsunternehmen entdecken